Over the past few decades, HIV treatment has advanced remarkably: simply by taking one pill each day, most patients can suppress the virus to the point where it’s undetectable and can’t be transmitted to someone else. While the therapy— generally a combination of three drugs in a single dose—has markedly slowed the HIV epidemic, it hasn’t stopped it entirely.
With more than $750 million raised already, the campaign creates a new synergy between Weill Cornell Medicine’s tri-partite mission to care, discover and teach, with a laser focus on three areas.
The spread of the Delta variant has put countries around the world on high alert.Dr. Roy M. Gulick, chief of the Division of Infectious Diseases at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and professor of medicine at Weill Cornell Medicine, answers questions about the new threat.
Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.
Weill Cornell Medicine has received a renewal of a prestigious grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to continue cutting-edge clinical research into treating and preventing infection with human immunodeficiency virus (HIV).
Critical care physicians, infectious disease specialists and pulmonologists from Weill Cornell Medicine and NewYork-Presbyterian have published a clinical practice guide for managing severe COVID-19 in the New England Journal of Medicine.
Dr. Henry Masur, M.D., ’72, chief of critical care medicine at the National Institutes of Health (NIH), has been awarded the Weill Cornell Medicine Alumni Association Award of Distinction.
As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.
Physicians, researchers and policymakers around the globe are grappling with the rise of antibiotic-resistant bacteria—a threat with the potential to derail decades of medical advances.
As therapies for HIV infection have advanced to help many patients control the infection as a chronic disease, investigators and patients have set their sights on a new goal—finding a cure.
